Stage 6 — Evaluate outcomes. Review the clinical, antimicrobial, prevention, and surveillance timeline and answer the three outcome questions.
Trend
Choose your responses, then check the answer.
Explanation
Outcome evaluation The response is effective because source control occurs promptly, drainage becomes contained, fever and leukocytosis resolve, erythema recedes, pain decreases, and broad empiric therapy is narrowed from microbiology and clinical response. Negative blood cultures do not erase the wound infection. Prevention review and NHSN classification remain separate from treatment: the team verifies prophylaxis, skin preparation, temperature, and glucose processes, assigns owners, and applies current surveillance criteria without claiming one variance caused the SSI. If prolonged IV vancomycin is truly needed for serious MRSA infection, AUC-guided monitoring is preferred to a universal trough-only target.
Measure the patient response Improvement is multidimensional: systemic findings resolve, the marked erythema contracts, pain and drainage diminish, and no deeper or organ-space complication appears.
Measure stewardship Appropriate empiric coverage is only the beginning. A strong result includes source control, culture interpretation, removal of unnecessary agents, patient-specific route and duration, and toxicity monitoring when needed.
Measure the system without false causality NHSN surveillance uses defined criteria. Quality review verifies prevention processes and tests improvement over time; it does not label one missed checkbox as the cause of an individual infection.
NCLEX rule Evaluate whether the source is controlled, the client is improving, therapy is narrower, and follow-up has owners.
Scenario (Stage 6 — Evaluate outcomes)Over the next two days, the surgical and antimicrobial plans are refined while infection prevention performs a separate surveillance and process review.
Clinical de-escalation — Reduction in antimicrobial spectrum, route intensity, monitoring burden, or duration when source control, microbiology, depth, and clinical response support it.
AUC-guided vancomycin monitoring — Exposure-based monitoring recommended for serious MRSA infection when vancomycin is continued; it should not be extrapolated as a mandatory target for every mild or noninvasive infection.
Process review without causal attribution — Verification of prevention steps, ownership, and remeasurement without claiming that one isolated variance necessarily caused one client's SSI.